SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – ENTERING INTO THE PRODUCT COMMISSIONED MANUFACTURING AND SUPPLY AGREEMENT WITH HUAHAI PHARMACEUTICAL

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 31 January 2023.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 31 January 2023, Shanghai Vinnerna Biosciences Co., Ltd.* (上海旺實生物醫藥科技有限公司) ("**Vinnerna Biosciences**"), a subsidiary controlled by the Company, and Zhejiang Huahai Pharmaceutical Co., Ltd.* (浙江華海藥業股份有限公司) ("**Huahai Pharmaceutical**") entered into the Product Commissioned Manufacturing and Supply Agreement (《產品委託生產及供貨協議》) (the "**Agreement**") in relation to the cooperation regarding the manufacturing and supply of Deuremidevir Hydrobromide Tablets (氫溴酸氘瑞米德韋片) (product code: VV116/JT001, "**VV116**"), an oral nucleoside analog anti-SARS-CoV-2 Category 1 innovative drug. Vinnerna Biosciences has authorized Huahai Pharmaceutical to manufacture and supply the active pharmaceutical ingredients ("**APIs**") for VV116 and has commissioned Huahai Pharmaceutical to manufacture the preparations for VV116 (the "**Transaction**").

MAIN CONTENT OF THE AGREEMENT

I. Scope of cooperation

(I) Pursuant to the agreed conditions and terms of the Agreement, Vinnerna Biosciences has authorized Huahai Pharmaceutical to manufacture and supply the APIs for VV116 and has commissioned Huahai Pharmaceutical to manufacture the finished doses for VV116.

(II) Huahai Pharmaceutical will cooperate with Vinnerna Biosciences to carry out the research and development works for the product including process optimization, quality research, pilot scale-up, process verification, to conduct related work including application for registration and production verification in accordance with relevant registration requirements, and to arrange for the manufacturing and supply of the product for Vinnerna Biosciences in accordance with the quality standards and production processes for APIs and preparations as approved by regulatory authorities.

II. Rights and obligations of both parties

(I) As the marketing authorization holder of the drug, Vinnerna Biosciences shall have all the rights and obligations in relation to the drug marketing authorization.

(II) Vinnerna Biosciences shall provide Huahai Pharmaceutical with relevant technical information on the product and provide support to Huahai Pharmaceutical during the process of technology transfer in relation to Huahai Pharmaceutical's research and manufacturing of APIs and its preparations.

(III) Huahai Pharmaceutical shall arrange for manufacturing in accordance with the quality standards and production processes as approved by regulatory authorities and as agreed with Vinnerna Biosciences.

III. Duration of the Agreement

The Agreement shall be valid for a period of ten years.

IV. Termination of the Agreement

Unless agreed by both parties through negotiation, neither party shall arbitrarily alter or terminate the Agreement. The expiration or termination of the Agreement for any reason shall not affect the rights and obligations of both parties that have accrued prior to the effective date of the expiration or termination of the Agreement.

V. Resolution of disputes

Any dispute arising from the implementation of the Agreement shall be settled by both parties through friendly negotiation. If such negotiation fails, the dispute shall be settled in the People's Court of the place where the plaintiff is domiciled.

VI. Applicable laws

The Agreement shall be governed by, interpreted and implemented in accordance with the laws of the People's Republic of China.

ABOUT VV116

VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase ("**RdRp**") of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect.

VV116 was jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences* (中國科學院上海藥物研究所), Wuhan Institute of Virology, Chinese Academy of Sciences* (中國科學院武漢病毒研究所), Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences* (中國科學院新疆理化技術研究所), Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences* (中國科學院中亞藥物研發中心)/ China-Uzbekistan Medicine Technical Park (the Belt and Road Joint Laboratory of the Ministry of Science and Technology)* (中烏醫藥科技城(科技部"一帶一路"聯合實驗室)), Lingang Laboratory* (臨港實驗室), Vigonvita Life Sciences Co., Ltd.* (蘇州旺山旺水生物醫藥有限公司) and the Company.

In December 2021, VV116 was approved for the treatment of moderate/severe coronavirus disease 2019 ("**COVID-19**") patients in Uzbekistan. On 28 January 2023, the National Medical Products Administration conditionally approved VV116 for the treatment of adult patients with mild to moderate COVID-19.

About Huahai Pharmaceutical

Company name: Zhejiang Huahai Pharmaceutical Co., Ltd.* (浙江華海藥業股份有限公司)
Legal representative: Chen Baohua (陳保華)
Registered capital: RMB1,483,474,941 (as at 30 September 2022)
Date of incorporation: 28 February 2001
Domicile: Xunqiao, Linhai City, Zhejiang Province

Business scope: licensed items: pharmaceutical production; pharmaceutical import and export; pharmaceutical wholesale; health food production; health food sales (as for items that shall be approved in accordance with the law, operating activities can only be carried out upon approval by relevant department, and the specific operating items shall be subject to the approval result). General items: technical service, technical development, technical consultation, technical exchange, technical transfer and technical promotion (the operating activities shall be carried out independently in accordance with the laws within the scope of business license except those items that shall be approved in accordance with the law).

According to the financial statements (audited) as disclosed by Huahai Pharmaceutical, as at 31 December 2021, the total assets of Huahai Pharmaceutical amounted to RMB15,468,124,894.16, and the net asset attributable to shareholders of the listed company amounted to RMB6,558,842,119.10. In 2021, Huahai Pharmaceutical recorded operating income amounting to RMB6,643,573,143.13 and net profit attributable to shareholders of the listed company amounting to RMB487,535,117.22.

To the best of the Company's knowledge and belief, having made all reasonable inquiries, Huahai Pharmaceutical and its ultimate beneficial owner are not connected persons of the Company (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited). As at the date of this announcement, Huahai Pharmaceutical holds 2,224,281 A shares of the Company, representing 0.23% of the total share capital of the Company.

Impact on the Company

1. The entering into of the Agreement will facilitate the establishment of a win-win strategic partnership on the basis of complementary strengths, mutual benefits and mutual development, further integrate mutual resources, and enhance the space for development of the Company's business, which satisfies the Company's future development needs.

2. The Transaction will not affect the independence of the Company's business, and the Company will not become dependent on the counterparty due to the Transaction.

3. The actual purchase amount of the Transaction is subject to uncertainties as affected by market demands. As at the date of announcement, the specific amount of the Agreement cannot be estimated.

Risk warning

The Company may be subject to the macroeconomic environment, industrial policies, market environment, management operation, etc. during the performance of the agreement, which may lead to change, suspension or termination of the Agreement. We kindly suggest that investors should make decisions in a prudent manner and be cautious of any investment risks.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 1 February 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai and Mr. Tang Yi as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* *For identification purpose only*